Chanyoung Kim
Primary Care · Los Angeles, CANPI 1003310517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$764
- Amgen$352
- Bayer$303
- Lilly USA, LLC$283
- Ardelyx, Inc.$249
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,023100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $1,154 |
| GSK | 35 | $764 |
| Amgen | 14 | $352 |
| Bayer | 14 | $303 |
| Lilly USA, LLC | 12 | $283 |
| Ardelyx, Inc. | 8 | $249 |
| Nestle Healthcare Nutrition Inc. | 10 | $228 |
| Boehringer Ingelheim | 9 | $206 |
| Sumitomo Pharma America, Inc. | 6 | $173 |
| Amarin Pharma, Inc. | 7 | $163 |
| Radius Health, Inc. | 7 | $159 |
| AstraZeneca | 6 | $147 |
| Exact Sciences | 3 | $83 |
| Pfizer | 3 | $78 |
| Aimmune Therapeutics, Inc. | 3 | $75 |
| Scilex Pharmaceuticals Inc. | 3 | $61 |
| IBSA Pharma Inc. | 3 | $56 |
| Almatica Pharma LLC | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 2 | $54 |
| Astellas Pharma US Inc | 2 | $46 |
| Vivus LLC | 2 | $43 |
| Merck | 2 | $41 |
| Boston Scientific | 2 | $40 |
| Shield Therapeutics Inc | 1 | $27 |
| Alvogen Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Abbott | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$5,023 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 28 | $29,566 |
| ZenpepLipase/Protease/Amylase | 17 | $26,393 |
| EliquisApixaban | 40 | $19,201 |
| TrulicityDulaglutide | 14 | $14,157 |
| LinzessLinaclotide | 25 | $13,988 |
| EntrestoSacubitril/Valsartan | 13 | $9,242 |
| MyrbetriqMirabegron | 12 | $5,821 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,082 |
| VascepaIcosapent Ethyl | 26 | $3,406 |
| JentaduetoLinagliptin/Metformin Hcl | 11 | $3,333 |
| LumiganBimatoprost | 12 | $3,145 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,524 |
| Atorvastatin Calcium | 211 | $2,222 |
| Amlodipine Besylate | 227 | $1,900 |
| Losartan Potassium | 167 | $1,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Lumigan | $1,154 | $46,69965 claims |
| Aimmune Therapeutics, Inc.Zenpep | $75 | $26,39317 claims |
| PfizerEliquis | $78 | $19,20140 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $283 | $14,85984 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $5,82112 claims |
| Boehringer IngelheimJentadueto | $206 | $3,33311 claims |
| Almatica Pharma LLCSertraline Hcl | $56 | $52474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 706 primary care providers in California.
Other primary care in Los Angeles
- Hamideh PourzandLos Angeles$103K
- Lisa HsiehLos Angeles$4K
- Leslie FletcherTorrance$1.8M
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.